Company profile
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33
- CEO
- Dr. Sandeep Chidambar Kulkarni M.D.
- Headquarters
- Henderson, NV, United States
- Employees
- 40
- IPO date
- Sep 3, 2021
- Sector
- Healthcare
- Industry
- Biotechnology